Last reviewed · How we verify
Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
Ara-C, Mitoxantrone, Daunorubicin, Thioguanin is a Combination chemotherapy regimen Small molecule drug developed by Prof. Dr. Wolfgang Hiddemann. It is currently in Phase 3 development for Acute myeloid leukemia (AML), Acute leukemia in adults.
This is a combination chemotherapy regimen that includes cytarabine (Ara-C), mitoxantrone, daunorubicin, and thioguanine, which work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.
This is a combination chemotherapy regimen that includes cytarabine (Ara-C), mitoxantrone, daunorubicin, and thioguanine, which work together to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Acute leukemia in adults.
At a glance
| Generic name | Ara-C, Mitoxantrone, Daunorubicin, Thioguanin |
|---|---|
| Sponsor | Prof. Dr. Wolfgang Hiddemann |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ara-C is a cytidine analog that inhibits DNA polymerase and incorporates into DNA to disrupt replication. Daunorubicin and mitoxantrone are topoisomerase II inhibitors that intercalate into DNA and prevent strand separation. Thioguanine is a purine analog that inhibits nucleotide synthesis. Together, these agents target rapidly dividing leukemic cells through multiple mechanisms of DNA damage and replication inhibition.
Approved indications
- Acute myeloid leukemia (AML)
- Acute leukemia in adults
Common side effects
- Myelosuppression/neutropenia
- Thrombocytopenia
- Anemia
- Mucositis
- Nausea and vomiting
- Infection
- Cardiotoxicity
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ara-C, Mitoxantrone, Daunorubicin, Thioguanin CI brief — competitive landscape report
- Ara-C, Mitoxantrone, Daunorubicin, Thioguanin updates RSS · CI watch RSS
- Prof. Dr. Wolfgang Hiddemann portfolio CI
Frequently asked questions about Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
What is Ara-C, Mitoxantrone, Daunorubicin, Thioguanin?
How does Ara-C, Mitoxantrone, Daunorubicin, Thioguanin work?
What is Ara-C, Mitoxantrone, Daunorubicin, Thioguanin used for?
Who makes Ara-C, Mitoxantrone, Daunorubicin, Thioguanin?
What drug class is Ara-C, Mitoxantrone, Daunorubicin, Thioguanin in?
What development phase is Ara-C, Mitoxantrone, Daunorubicin, Thioguanin in?
What are the side effects of Ara-C, Mitoxantrone, Daunorubicin, Thioguanin?
Related
- Drug class: All Combination chemotherapy regimen drugs
- Manufacturer: Prof. Dr. Wolfgang Hiddemann — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML)
- Indication: Drugs for Acute leukemia in adults
- Compare: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin vs similar drugs
- Pricing: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin cost, discount & access